112 related articles for article (PubMed ID: 10094881)
1. Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses.
Zhang Z; Barnhill SD; Zhang H; Xu F; Yu Y; Jacobs I; Woolas RP; Berchuck A; Madyastha KR; Bast RC
Gynecol Oncol; 1999 Apr; 73(1):56-61. PubMed ID: 10094881
[TBL] [Abstract][Full Text] [Related]
2. Preoperative determination of CASA (Cancer Associated Serum Antigen) and CA-125 for the discrimination between benign and malignant pelvic tumor mass: a prospective study.
Sehouli J; Akdogan Z; Heinze T; Könsgen D; Stengel D; Mustea A; Lichtenegger W
Anticancer Res; 2003; 23(2A):1115-8. PubMed ID: 12820357
[TBL] [Abstract][Full Text] [Related]
3. The role of serum tetranectin, CA 125, and a combined index as tumor markers in women with pelvic tumors.
Høgdall CK; Mogensen O; Tabor A; Mogensen B; Jakobsen AK; Nørgaard-Pedersen B; Larsen SO; Clemmensen I
Gynecol Oncol; 1995 Jan; 56(1):22-8. PubMed ID: 7821842
[TBL] [Abstract][Full Text] [Related]
4. Preoperative serum tumor-associated antigen levels in women with pelvic masses.
Soper JT; Hunter VJ; Daly L; Tanner M; Creasman WT; Bast RC
Obstet Gynecol; 1990 Feb; 75(2):249-54. PubMed ID: 2300353
[TBL] [Abstract][Full Text] [Related]
5. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer.
Jiang XT; Tao HQ; Zou SC
Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):464-8. PubMed ID: 15313690
[TBL] [Abstract][Full Text] [Related]
6. Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer.
Zhang Z; Yu Y; Xu F; Berchuck A; van Haaften-Day C; Havrilesky LJ; de Bruijn HW; van der Zee AG; Woolas RP; Jacobs IJ; Skates S; Chan DW; Bast RC
Gynecol Oncol; 2007 Dec; 107(3):526-31. PubMed ID: 17920110
[TBL] [Abstract][Full Text] [Related]
7. The differential diagnostic potential of a panel of tumor markers (CA 125, CA 15-3, and CA 72-4 antigens) in patients with a pelvic mass.
Schutter EM; Davelaar EM; van Kamp GJ; Verstraeten RA; Kenemans P; Verheijen RH
Am J Obstet Gynecol; 2002 Aug; 187(2):385-92. PubMed ID: 12193930
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of CA 125 levels in differentiating malignant from benign tumors in patients with pelvic masses.
Chen DX; Schwartz PE; Li XG; Yang Z
Obstet Gynecol; 1988 Jul; 72(1):23-7. PubMed ID: 3164105
[TBL] [Abstract][Full Text] [Related]
9. [Diagnostic significance of preoperative determination of CA-125 serum levels in the differentiation of malignant and benign pelvic masses].
Durdević S; Segedi D; Vejnović T; Radeka G
Med Pregl; 1992; 45(7-8):262-5. PubMed ID: 1344453
[TBL] [Abstract][Full Text] [Related]
10. Significance of CA 125 serum level in discrimination between benign and malignant masses in the pelvis.
Milojkovic M; Hrgovic Z; Hrgovic I; Jonat W; Maass N; Buković D
Arch Gynecol Obstet; 2004 Mar; 269(3):176-80. PubMed ID: 14557888
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic value of serum CA242, CA 19-9, CA 15-3 and CA 125 in patients with carcinoma of the gallbladder.
Shukla VK; Gurubachan ; Sharma D; Dixit VK; Usha
Trop Gastroenterol; 2006; 27(4):160-5. PubMed ID: 17542293
[TBL] [Abstract][Full Text] [Related]
12. Urinary gonadotropin peptide (UGP) and serum CA 125 in gynaecologic practice, a clinical prospective study.
Schutter EM; Mijatovic V; Kok A; Van Kamp GJ; Verstraeten R; Verheijen RH
Anticancer Res; 1999; 19(6C):5551-7. PubMed ID: 10697615
[TBL] [Abstract][Full Text] [Related]
13. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.
Moore RG; Brown AK; Miller MC; Skates S; Allard WJ; Verch T; Steinhoff M; Messerlian G; DiSilvestro P; Granai CO; Bast RC
Gynecol Oncol; 2008 Feb; 108(2):402-8. PubMed ID: 18061248
[TBL] [Abstract][Full Text] [Related]
14. Relationship of serum levels of tumor markers with tissue expression of gene products in ovarian carcinoma.
Sorak M; Arsenijević S; Lukić G; Arsenijević N; Ristić P; Pavlović S; Popović S; Baskić D
J BUON; 2007; 12(1):99-104. PubMed ID: 17436409
[TBL] [Abstract][Full Text] [Related]
15. The measurement of urinary beta core fragment in conjunction with serum CA125 does not aid the differentiation of malignant from benign pelvic masses.
Carter PG; Iles RK; Neven P; Davies AP; Shepherd JH; Chard T
Gynecol Oncol; 1993 Dec; 51(3):368-71. PubMed ID: 8112647
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798
[TBL] [Abstract][Full Text] [Related]
17. Estimation of probability of malignancy using a logistic model combining physical examination, ultrasound, serum CA 125, and serum CA 72-4 in postmenopausal women with a pelvic mass: an international multicenter study.
Schutter EM; Sohn C; Kristen P; Möbus V; Crombach G; Kaufmann M; Caffier H; Kreienberg R; Verstraeten AA; Kenemans P
Gynecol Oncol; 1998 Apr; 69(1):56-63. PubMed ID: 9570999
[TBL] [Abstract][Full Text] [Related]
18. Prediction of pelvic organ prolapse using an artificial neural network.
Robinson CJ; Swift S; Johnson DD; Almeida JS
Am J Obstet Gynecol; 2008 Aug; 199(2):193.e1-6. PubMed ID: 18533119
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis of pancreatic carcinoma based on combined measurement of multiple serum tumor markers using artificial neural network analysis.
Yang Y; Chen H; Wang D; Luo W; Zhu B; Zhang Z
Chin Med J (Engl); 2014; 127(10):1891-6. PubMed ID: 24824251
[TBL] [Abstract][Full Text] [Related]
20. A multicentre evaluation of the CA 15-3 assay, CA 19-9 assay and CA 125 II assay on the Bayer Immuno 1 System.
Römer M; Haeckel R; Brux B; Sinha P; Raiko I; Krieg M; Stark M; Seidel D; Hübner U; Schmitz G
Eur J Clin Chem Clin Biochem; 1997 Aug; 35(8):637-44. PubMed ID: 9298356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
